Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR)’s share price traded down 4.1% during mid-day trading on Friday . The stock traded as low as $16.00 and last traded at $16.02, with a volume of 102,701 shares changing hands. The stock had previously closed at $16.70.

Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, June 13th. Wedbush assumed coverage on Eiger BioPharmaceuticals in a report on Wednesday, June 1st. They issued an “outperform” rating and a $36.00 target price for the company. Jefferies Group reaffirmed a “buy” rating on shares of Eiger BioPharmaceuticals in a report on Monday, May 16th. Finally, Oppenheimer Holdings Inc. assumed coverage on Eiger BioPharmaceuticals in a report on Tuesday, July 5th. They issued an “outperform” rating and a $34.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Eiger BioPharmaceuticals presently has a consensus rating of “Buy” and an average price target of $34.50.

The stock’s market capitalization is $113.81 million. The firm’s 50-day moving average is $18.50 and its 200 day moving average is $18.52.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its earnings results on Wednesday, August 10th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by $0.70. On average, equities research analysts predict that Eiger BioPharmaceuticals Inc. will post ($8.81) EPS for the current year.

In other Eiger BioPharmaceuticals news, CFO James H. Welch bought 2,500 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was purchased at an average cost of $19.80 per share, for a total transaction of $49,500.00. Following the completion of the acquisition, the chief financial officer now owns 2,000 shares of the company’s stock, valued at $39,600. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James P. Shaffer bought 1,250 shares of the stock in a transaction dated Monday, June 13th. The shares were acquired at an average price of $22.17 per share, with a total value of $27,712.50. Following the completion of the acquisition, the insider now directly owns 1,975 shares of the company’s stock, valued at approximately $43,785.75. The disclosure for this purchase can be found here.

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.